Leah Lawrence
Abstract
Relapsed or refractory multiple myeloma patients experience high response rates, overall survival with bortezomib-based therapy.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Relapsed or refractory multiple myeloma patients experience high response rates, overall survival with bortezomib-based therapy.
Key concepts: Bortezomib, Refractory (planetary science), Multiple myeloma, Medicine, Carfilzomib, Oncology, Internal medicine, Astrobiology